Marketing authorisations, variations and licensing guidance

Get emails for this topic

Services

• Sunset clause: request for public health exemption

  Apply for a public health exemption from the sunset clause.

See more services in this topic

Guidance and regulation

• Apply for a licence to market a medicine in the UK
  • Detailed guide
  • 14 May 2024
  • Medicines and Healthcare products Regulatory Agency
• Medicines: packaging, labelling and patient information leaflets
  • Detailed guide
  • 7 March 2024
  • Medicines and Healthcare products Regulatory Agency
• Medicines: reclassify your product
  • Detailed guide
  • 27 September 2024
  • Medicines and Healthcare products Regulatory Agency
• Medicines: apply for a variation to your marketing authorisation
  • Detailed guide
  • 22 April 2024
  • Medicines and Healthcare products Regulatory Agency
• Early Access to Medicines Scheme - Information for Applicants
  • Detailed guide
  • 12 November 2024
  • Medicines and Healthcare products Regulatory Agency

See more guidance and regulation in this topic

News and communications

• Sparsentan approved to treat adult patients with primary immunoglobulin A nephropathy (IgAN)
  • 18 November 2024
  • Medicines and Healthcare products Regulatory Agency
  • News story
• Great Britain Marketing Authorisations (MAs) for Centrally Authorised Products (CAPs)
  • 15 November 2024
  • Medicines and Healthcare products Regulatory Agency
  • Decision
• Orphan registered medicinal products
  • 8 November 2024
  • Medicines and Healthcare products Regulatory Agency
  • Decision
• Sugemalimab approved to treat adult patients with non-small cell lung cancer     
  • 30 October 2024
  • Medicines and Healthcare products Regulatory Agency
  • Press release
• Statutory Instrument laid in Parliament provides first regulatory framework of its kind that will transform the manufacture of innovative medicines at the point of patient care
  • 21 October 2024
  • Medicines and Healthcare products Regulatory Agency
  • Press release

See more news and communications in this topic

Research and statistics

• Early access to medicines scheme applications: pending, refused, granted
  • 8 November 2023
  • Medicines and Healthcare products Regulatory Agency
  • Official statistics
• Medicines: licensing time-based performance measures
  • 31 January 2023
  • Medicines and Healthcare products Regulatory Agency
  • Official statistics
• Public Assessment Report of the Reclassification of Nasacort Allergy Relief for Adults 55 micrograms/dose, nasal spray, suspension
  • 26 May 2021
  • Medicines and Healthcare products Regulatory Agency
  • Research
• Public Assessment Report of the Reclassification of Almerg 180mg film-coated tablets
  • 26 April 2021
  • Medicines and Healthcare products Regulatory Agency
  • Research
• Public Assessment Report of the Reclassification of Allevia 120mg Tablets
  • 22 December 2020
  • Medicines and Healthcare products Regulatory Agency
  • Research

See more research and statistics in this topic

Policy papers and consultations

• Consultation on proposal to make Aquiette 2.5mg Tablets (oxybutynin hydrochloride) available from pharmacies
  • 3 July 2023
  • Medicines and Healthcare products Regulatory Agency
  • Consultation outcome
  • Date closed 13 May 2022
• The future strategy for batch testing of medicinal products in Great Britain
  • 15 December 2022
  • Department of Health and Social Care
  • Consultation outcome
  • Date closed 26 July 2022

See more policy papers and consultations in this topic

Organisations

• Medicines & Healthcare products Regulatory Agency
• Department of Health & Social Care